Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Guardant Health, Inc.
  6. Summary
    GH   US40131M1099

GUARDANT HEALTH, INC.

(GH)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
43.66 USD   +8.23%
06/21GUARDANT HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/14TRANSCRIPT : Guardant Health, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 09:20 AM
CI
06/13Guardant Health Closes Guardant Health AMEA Joint Venture Buyout for $177.8 Million
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
44.41(c) 42.26(c) 42.04(c) 40.34(c) 43.66(c) Last
1 159 693 947 724 1 040 786 1 365 882 833 629 Volume
-3.98% -4.84% -0.52% -4.04% +8.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 466 M - -
Net income 2022 -508 M - -
Net Debt 2022 336 M - -
P/E ratio 2022 -9,05x
Yield 2022 -
Sales 2023 625 M - -
Net income 2023 -481 M - -
Net Debt 2023 547 M - -
P/E ratio 2023 -9,50x
Yield 2023 -
Capitalization 4 450 M 4 450 M -
EV / Sales 2022 10,3x
EV / Sales 2023 8,00x
Nbr of Employees 1 373
Free-Float 95,3%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. It has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need... 
Read more
More about the company
Ratings of Guardant Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GUARDANT HEALTH, INC.
06/21GUARDANT HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/14TRANSCRIPT : Guardant Health, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare..
CI
06/13Guardant Health Closes Guardant Health AMEA Joint Venture Buyout for $177.8 Million
MT
06/13GUARDANT HEALTH : Completes Purchase of Guardant Health AMEA Joint Venture - Form 8-K
PU
06/13Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
BU
06/13GUARDANT HEALTH, INC. : Termination of a Material Definitive Agreement, Other Events, Fina..
AQ
06/07TRANSCRIPT : Guardant Health, Inc. Presents at William Blair’s 42nd Annual Growth Sto..
CI
06/03Piper Sandler Starts Guardant Health at Overweight With $65 Price Target
MT
05/26Guardant Health to Participate in Upcoming June Investor Conferences
BU
05/25First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d..
BU
05/25First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational At Vall d..
CI
05/23Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 Ame..
BU
05/21Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal C..
BU
05/21Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colore..
CI
05/10TRANSCRIPT : Guardant Health, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
More news
News in other languages on GUARDANT HEALTH, INC.
06/13Guardant Health conclut le rachat de la coentreprise Guardant Health AMEA pour 177,8 mi..
05/26Erste Dienstleistung von Guardant Health für Flüssigbiopsie-Tests in Europa jetzt in Be..
05/26Le premier service de test de biopsie liquide de Guardant Health en Europe est désormai..
05/25VHIO se sitúa como referente en el uso de biopsia líquida gracias a la incorporación, p..
05/25Le premier service de test de biopsie liquide de Guardant Health en Europe est maintena..
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 43,66 $
Average target price 111,75 $
Spread / Average Target 156%
EPS Revisions
Managers and Directors
Helmy Eltoukhy Chairman & Co-Chief Executive Officer
AmirAli H. Talasaz Co-Chief Executive Officer & Director
Michael Bell Chief Financial & Accounting Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capi. (M$)
GUARDANT HEALTH, INC.-56.35%4 450
EXACT SCIENCES CORPORATION-49.39%6 930
BGI GENOMICS CO., LTD.-19.24%4 387
IOVANCE BIOTHERAPEUTICS, INC.-39.92%1 735
BEIJING STRONG BIOTECHNOLOGIES, INC.-12.36%1 520
SEEGENE, INC.-44.43%1 439